Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1.

Chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of different tissue markers. Seventeen lung cancer tissue blocks obtained by bronchoscopic biopsies together with their corresponding surgical biopsies after neoadjuvant chemotherapy were studied.

Elevated anti-cholesterol antibody levels in the sera of non-small cell lung cancer patients.

There have been no published data yet on the serum level of antibodies against cholesterol (anti-cholesterol antibodies) in oncological patients. We decided to examine these levels in the sera of non-small cell lung cancer (NSCLC) patients. Measurements were performed by ELISA technique in the sera of 44 NSCLC patients and the results were compared to the anti-cholesterol antibody levels of 34 non-tumorous control subjects.

[The role of adjuvant chemotherapy in the treatment of non-small cell lung cancer].

Unlabelled: Postoperative treatments for lung cancer have been evaluated for more than two decades, but in the majority of the studies (especially until 1990) no significant effect on survival has been shown. In 1995, a meta-analysis of eight cisplatin-based adjuvant chemotherapy trials with NSCLC showed a 13% reduction in the risk of death (P=0.08) and 5% benefit in 5-year survival.

The immunodiagnosis of lung cancer with monoclonal antibodies.

Lung cancer is responsible for much suffering and death worldwide. The only hope for cure is therapy applied in an early phase, and all methods of diagnosis should be aimed at this goal. This paper reviews the development of the use of monoclonal antibodies in the diagnosis of lung cancer.